ArticleSLAS discovery : advancing life sciences R & D2026
A Hybrid Experimental and in silico Platform for ITPK1 Chemical Probe Discovery.
Article in SLAS discovery : advancing life sciences R & D, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Inositol-tetrakisphosphate 1-kinase (ITPK1) is a pivotal enzyme in the inositol phosphate signaling pathway that functions to maintain the balance of inositol phosphate (IP) species. Dysregulation of this pathway has been linked to human disease, making ITPK1 an attractive therapeutic target. While high-throughput screening (HTS) is a traditional strategy for identifying small molecule inhibitors, integrating computational approaches can significantly speed up and enhance hit rates. Here, we developed a hybrid experimental and virtual approach towards the identification of ITPK1 chemical probe candidates. We first miniaturized an ITPK1 enzymatic assay to 1536-well format and screened ∼19,000 annotated and chemically diverse compounds. We then utilized the resulting dataset to develop Machine Learning (ML) and Pharmacophore (PH4) models to virtually screen a larger library of 120,000 compounds to expand the chemical diversity of the screening set. Importantly, our screening platform included a selectivity assay against PPIP5K2, the closest structural relative of ITPK1. The identified hits were evaluated for ITPK1 binding, including via a novel high-throughput Structure Dynamic Response (SDR) target engagement assay. Hits underwent further confirmation through orthogonal assays and mechanistic investigation, including obtaining a co-crystal structure for one of the hits. This integrated workflow-combining physical HTS with computational modeling-led to the identification of two novel candidate inhibitors. This study demonstrates an efficient, scalable strategy for targeting ITPK1 and offers a promising platform for drug discovery efforts in diseases linked to perturbed inositol phosphate pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.